David H Gutmann Selected Research

Neurofibromatoses (Neurofibromatosis)

1/2022	Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
1/2021	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
1/2021	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
10/2020	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
6/2017	The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
1/2016	Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma.
4/2015	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
4/2013	Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy.
6/2012	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
11/2005	Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David H Gutmann Research Topics

Disease

101	Neoplasms (Cancer) 01/2022 - 04/2002
57	Glioma (Gliomas) 10/2022 - 03/2002
32	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2022 - 08/2002
24	Brain Neoplasms (Brain Tumor) 10/2022 - 03/2002
24	Optic Nerve Glioma 01/2022 - 11/2005
23	Meningioma (Meningiomas) 01/2019 - 05/2002
22	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 02/2002
22	Tuberous Sclerosis (Bourneville's Disease) 12/2017 - 06/2002
18	Neurofibrosarcoma (MPNST) 07/2020 - 03/2002
15	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2022 - 09/2002
13	Neurofibromatoses (Neurofibromatosis) 01/2022 - 08/2002
10	Neurilemmoma (Schwannoma) 02/2015 - 12/2002
8	Glioblastoma (Glioblastoma Multiforme) 12/2019 - 03/2002
8	Seizures (Absence Seizure) 12/2017 - 06/2002
7	Epilepsy (Aura) 12/2017 - 08/2003
6	Gliosis 01/2021 - 08/2003
5	Neurofibroma 01/2022 - 09/2002
5	Plexiform Neurofibroma 01/2021 - 04/2004
5	Neoplasm Metastasis (Metastasis) 11/2020 - 02/2004
5	Autistic Disorder (Autism) 11/2019 - 06/2002
5	Carcinogenesis 11/2007 - 07/2002
4	Schwannomatosis 01/2022 - 10/2008
3	Brain Diseases (Brain Disorder) 11/2019 - 10/2012
3	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2019 - 03/2008
3	Hamartoma 01/2019 - 06/2002
3	Sarcoma (Soft Tissue Sarcoma) 06/2017 - 04/2011
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2017 - 03/2008
3	Disease Progression 01/2017 - 12/2008
3	Necrosis 02/2015 - 12/2008
3	Ependymoma 01/2014 - 05/2002
3	Adenocarcinoma 05/2006 - 08/2002
2	Inflammation (Inflammations) 10/2019 - 06/2013
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2018 - 12/2017
2	Hepatocellular Carcinoma (Hepatoma) 03/2012 - 05/2008
2	Learning Disabilities (Learning Disability) 10/2008 - 08/2002
2	Peripheral Nervous System Neoplasms 12/2005 - 02/2004
2	Intellectual Disability (Idiocy) 04/2004 - 06/2002
2	Focal Cortical Dysplasia 11/2003 - 06/2002
2	Central Nervous System Neoplasms 08/2002 - 05/2002

Drug/Important Bio-Agent (IBA)

45	Proteins (Proteins, Gene)FDA Link 11/2020 - 03/2002
26	Neurofibromin 1 (Neurofibromin)IBA 01/2018 - 07/2002
22	Neurofibromin 2 (Merlin)IBA 01/2014 - 05/2002
18	trans-sodium crocetinate (crocetin)IBA 12/2017 - 06/2002
14	Biomarkers (Surrogate Marker)IBA 06/2017 - 12/2004
12	Biological ProductsIBA 01/2021 - 05/2002
10	TOR Serine-Threonine KinasesIBA 10/2020 - 04/2005
8	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2003
8	Pharmaceutical PreparationsIBA 05/2019 - 06/2003
7	Sirolimus (Rapamycin)FDA Link 12/2017 - 04/2008
7	ErbB Receptors (EGF Receptor)IBA 01/2017 - 03/2003
6	Retinaldehyde (Retinal)IBA 01/2019 - 09/2002
6	Small Interfering RNA (siRNA)IBA 04/2016 - 03/2006
6	DNA (Deoxyribonucleic Acid)IBA 03/2012 - 05/2002
4	MitogensIBA 01/2022 - 10/2015
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 09/2007
4	ChemokinesIBA 01/2020 - 10/2015
4	Glial Fibrillary Acidic ProteinIBA 12/2017 - 02/2002
4	epidermal growth factor receptor VIIIIBA 01/2017 - 03/2003
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 09/2005
4	Messenger RNA (mRNA)IBA 11/2008 - 08/2004
4	Tuberous Sclerosis Complex 2 ProteinIBA 09/2004 - 09/2002
3	CytokinesIBA 01/2021 - 01/2016
3	Transcription Factors (Transcription Factor)IBA 01/2021 - 07/2005
3	Cyclic AMP (AMP, Cyclic)IBA 10/2020 - 09/2007
3	MicroRNAs (MicroRNA)IBA 12/2019 - 01/2013
3	LigandsIBA 10/2019 - 02/2004
3	Phosphotransferases (Kinase)IBA 12/2017 - 11/2003
3	Monomeric GTP-Binding ProteinsIBA 06/2015 - 09/2002
3	Mitogen-Activated Protein KinasesIBA 01/2015 - 06/2003
3	RolipramIBA 07/2010 - 10/2008
3	OligonucleotidesIBA 03/2006 - 08/2002
3	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 11/2004 - 08/2003
2	Neutralizing AntibodiesIBA 01/2022 - 10/2015
2	Uvitex SWN (SWN)IBA 01/2022 - 06/2017
2	Glycoproteins (Glycoprotein)IBA 10/2021 - 10/2019
2	NestinIBA 01/2021 - 01/2005
2	Everolimus FDA Link 01/2021 - 10/2020
2	MTOR InhibitorsIBA 10/2020 - 02/2015
2	CC ChemokinesIBA 10/2019 - 10/2015
2	SpectrinIBA 01/2018 - 09/2015
2	Indicators and Reagents (Reagents)IBA 03/2015 - 12/2013
2	Dopamine (Intropin)FDA LinkGeneric 02/2014 - 04/2013
2	Proto-Oncogene Proteins B-rafIBA 10/2013 - 12/2012
2	Anticonvulsants (Antiepileptic Drugs)IBA 10/2013 - 08/2007
2	Superoxide DismutaseIBA 01/2011 - 03/2008
2	Hormones (Hormone)IBA 08/2010 - 09/2002
2	Progesterone Receptors (Progesterone Receptor)IBA 08/2010 - 12/2004
2	H-cadherin (T-cadherin)IBA 05/2008 - 01/2003
2	ManganeseIBA 03/2008 - 05/2007
2	Glutamic Acid (Glutamate)FDA Link 11/2007 - 08/2003
2	Tumor Suppressor Protein p14ARF (p14ARF)IBA 03/2006 - 11/2004
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2005 - 08/2002
2	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 04/2005 - 01/2003
2	Cell Adhesion Molecule-1IBA 12/2004 - 10/2004
2	Growth Factor ReceptorsIBA 04/2004 - 09/2002
1	Cyclic NucleotidesIBA 01/2022
1	alpha2 Subunit Collagen Type IIBA 01/2022

Therapy/Procedure

55	Therapeutics 10/2022 - 03/2002
12	Drug Therapy (Chemotherapy) 01/2022 - 12/2004
2	Aftercare (After-Treatment) 01/2021 - 12/2020